Fidelity Investments’s Candel Therapeutics CADL Stock Holding History

Fidelity Investments’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.8M	Buy	10,987,017 +2,752,718	+33%	+$15M	﹤0.01%	1403
2025 Q4	$46.5M	Buy	8,234,299 +914	+0%	+$4.92K	﹤0.01%	1473
2025 Q3	$42M	Sell	8,233,385 -50	-0%	-$289	﹤0.01%	1500
2025 Q2	$41.7M	Buy	8,233,435 +1,148,119	+16%	+$5.91M	﹤0.01%	1461
2025 Q1	$40M	Buy	7,085,316 +3,161,717	+81%	+$25.8M	﹤0.01%	1433
2024 Q4	$34.1M	Buy	3,923,599 +3,917,026	+59,593%	+$23.1M	﹤0.01%	1533
2024 Q3	$45.6K	Buy	+6,573	New	+$40.8K	﹤0.01%	3818
2024 Q1	–	Sell	-298,384	Closed	-$439K	–	5393
2023 Q4	$439K	Sell	298,384 -140,674	-32%	-$137K	﹤0.01%	2719
2023 Q3	$408K	Sell	439,058 -13,499	-3%	-$15.6K	﹤0.01%	2678
2023 Q2	$570K	Sell	452,557 -160,600	-26%	-$237K	﹤0.01%	2615
2023 Q1	$840K	Sell	613,157 -124,439	-17%	-$243K	﹤0.01%	2558
2022 Q4	$1.32M	Sell	737,596 -161,803	-18%	-$320K	﹤0.01%	2479
2022 Q3	$2.82M	Hold	899,399	–	–	﹤0.01%	2338
2022 Q2	$2.91M	Sell	899,399 -1,072,827	-54%	-$4.3M	﹤0.01%	2384
2022 Q1	$10M	Sell	1,972,226 -290,616	-13%	-$1.44M	﹤0.01%	2118
2021 Q4	$17.7M	Sell	2,262,842 -237,158	-9%	-$2.3M	﹤0.01%	1886
2021 Q3	$27.1M	Buy	+2,500,000	New	+$20.7M	﹤0.01%	1689

Other funds holding CADL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HFF

Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return

Fidelity Investments's CADL Position: Q1 2026 in Review

Fidelity Investments increased its Candel Therapeutics (CADL) stake by 33% in Q1 2026, buying an estimated $15M and bringing the position to 10,987,017 shares worth $53.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1403.

Fidelity Investments first reported a position in CADL in Q3 2021 and has held it in 17 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Fidelity Investments held 10,987,017 shares of Candel Therapeutics worth $53.8M as of Q1 2026.
Fidelity Investments bought 2,752,718 Candel Therapeutics shares in Q1 2026, an estimated $15M.
Candel Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1403 holding.
Fidelity Investments first reported a position in Candel Therapeutics in Q3 2021 and has held it in 17 quarters since.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.